Nkarta, Inc.
NASDAQ:NKTXBiotechnology
+$0.09 today
- Market cap
- $82.37M
- Beta
- 0.90
- P/E (TTM)
- -2.0
- EPS (TTM)
- -$1.35
Volume 0.81M
Average 0.75M
NKTX Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Nkarta, Inc.NASDAQ: NKTX
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income declines year over year
Q1 FY2026 net income of $27.83M (cash outflow) fell 13.0% year over year, behind the -10.2% change in trailing-twelve-month net income. Sequentially, it rose 1.5% from the prior quarter. Over 3 fiscal years it compounded at -2.9% a year.
Context
- Net income grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 5 analysts of -$117.11M (+12.5%) for the fiscal year ending Dec 2026, a step up from the -4.3% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$27.83M+1.5% QoQ
- Last fiscal yearDec 2025
- -$104.08M-4.3% YoY
- LTMMar 2026
- -$99.93M-10.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -13.0% | +17.6% | +30.6 pp |
| 1 year | -4.3% | +12.5% | +16.8 pp |
| 3-year CAGR | -2.9% | -6.3% | -3.4 pp |
| 5-year CAGR | -16.0% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (104.08M) USD
- Year-over-year change
- +4.3%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (104.08M) | +4.3% |
| FY2024 | 2024-12-31 | (108.79M) | +7.4% |
| FY2023 | 2023-12-31 | (117.5M) | -3.2% |
| FY2022 | 2022-12-31 | (113.84M) | -32.3% |
| FY2021 | 2021-12-31 | (86.08M) | — |
Net Income vs competitors
How NKTX compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -10.2% is the 5th highest of 8, against a peer median of +1.6%.
- Over three fiscal years its annual growth of -2.9% compares with a peer median of +10.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $883.08M USD | +644.6% | +96.2% | — | |
| LTM Mar 2026 | $129.91M USD | -26.1% | -21.5% | 2056.8% | |
| LTM Mar 2026 | $125.39M USD | +1.6% | +2.3% | 680.8% | |
| LTM Mar 2026 | $99.93M USD | -10.2% | -2.9% | — | |
| LTM Mar 2026 | $77.22M USD | -24.4% | +9.1% | — | |
| LTM Mar 2026 | $75.86M USD | +73.5% | +71.0% | — | |
| LTM Mar 2026 | CHF 64.16M CHF | +7.8% | — | — | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $40.19M USD | -21.6% | +11.9% | — |
| Peer median (excluding NKTX) | — | +1.6% | +10.5% | 1368.8% | |
Competitors are the stored peer set for NKTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (86.08M) | (113.84M) | (117.5M) | (108.79M) | (104.08M) |
| Depreciation & Amortization | 1.76M | 2.64M | 5.87M | 2.24M | 4.61M |
| Deferred Income Tax | 3.24M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 14.46M | 16.86M | 17.2M | 16.73M | 8.56M |
| Change in Working Capital | (1.64M) | 33.74M | 10.93M | (12.16M) | (435K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.79M | 2.76M | 4.22M | (4.47M) | 2.46M |
| Other Working Capital | (4.44M) | 30.98M | 6.7M | (7.69M) | (2.9M) |
| Other Non-Cash Items | 337K | 3.61M | (2.65M) | 2.29M | 2.65M |
| Operating Cash Flow | (67.93M) | (57M) | (86.16M) | (99.7M) | (88.7M) |
| Capital Expenditures | (5.03M) | (47.11M) | (28.15M) | (4.41M) | (1.21M) |
| Acquisitions (Net) | (37.56K) | 137.58K | 0 | 0 | 0 |
| Purchases of Investments | (227.28M) | (385.89M) | (260.23M) | (406.38M) | (238.57M) |
| Sales of Investments | 264.84M | 248.31M | 367.4M | 281.23M | 340.09M |
| Other Investing Activities | 37.56K | (137.58K) | 0 | 0 | 0 |
| Investing Cash Flow | 32.53M | (184.69M) | 79.02M | (129.56M) | 100.32M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 1.2M | 217.17M | 691K | 225.07M | 141K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 1.84M | 0 | 1.01M | 0 |
| Financing Cash Flow | 1.2M | 219.01M | 691K | 226.08M | 141K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (34.19M) | (22.68M) | (6.45M) | (3.17M) | 11.76M |
| Free Cash Flow | (72.95M) | (104.11M) | (114.31M) | (104.11M) | (89.91M) |
Nkarta, Inc.
NASDAQ:NKTX
Intrinsic Alpha fair value
Locked
Current Price
$1.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.